title: Ophthalmic artery chemosurgery for retinoblastoma prevents new intraocular tumors.
abstract: OBJECTIVE
  To determine the incidence and timing of new intraocular tumor foci in genetic retinoblastoma cases after treatment with ophthalmic artery chemosurgery (OAC).
  
  
  METHODS
  Single-center retrospective review of all genetic retinoblastoma cases managed at Memorial Sloan-Kettering Cancer Center/Weil-Cornell Medical School since May 2006.
  
  
  METHODS
  Eighty-one patients (80 with bilateral disease and 1 with unilateral disease with a family history) with genetic retinoblastoma, with a total of 116 eyes treated with OAC since May 2006.
  
  
  METHODS
  Retrospective, single-institution review of patients with bilateral retinoblastoma and unilateral retinoblastoma with a positive family history. New tumors were assessed by clinical notes, retinal drawings, and RetCam digital imaging (Clarity Medical Systems, Pleasanton, CA).
  
  
  METHODS
  New intraocular retinoblastoma tumors after treatment with OAC.
  
  
  RESULTS
  Forty-one eyes were treated primarily with OAC (treatment-naïve group) and 75 eyes were treated with OAC after prior treatment with systemic chemotherapy, external beam radiation, or both and focal techniques. Of the 41 treatment-naïve eyes, a new intraocular tumor (one focus) subsequently developed in 1 eye. Of the 75 previously treated eyes, new tumors (single focus in each eye) subsequently developed in 6 eyes.
  
  
  CONCLUSIONS
  Eyes receiving OAC demonstrate fewer new intraocular retinoblastomas after radiation or systemic chemotherapy than has been reported in the literature. This suggests that ophthalmoscopically undetectable tumors are present at the initial diagnosis and effectively are eliminated as a result of OAC.
authors.affiliation: Department of Ophthalmology at Weill-Cornell Medical School, New York, New York; Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: abramsod@mskcc.org.
authors.forename: David H
authors.initials: DH
authors.lastname: Abramson
authors.affiliation: Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Jasmine H
authors.initials: JH
authors.lastname: Francis
authors.affiliation: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Pediatrics, Weill-Cornell Medical Center, New York, New York.
authors.forename: Ira J
authors.initials: IJ
authors.lastname: Dunkel
authors.affiliation: Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, New York.
authors.forename: Brian P
authors.initials: BP
authors.lastname: Marr
authors.affiliation: Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York.
authors.forename: Scott E
authors.initials: SE
authors.lastname: Brodie
authors.affiliation: Ophthalmic Oncology Service at Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Neurosurgery, Neurology, and Radiology at Weill-Cornell Medical, New York, New York.
authors.forename: Y Pierre
authors.initials: YP
authors.lastname: Gobin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D009880:Ophthalmic Artery / Q000187:drug effects*; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D012175:Retinoblastoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D012189:Retrospective Studies